ASXL1 and myelodysplastic syndrome: A retrospective study found that in MDS patients with ASXL1 mutations, the combination of HMAs and Venetoclax (VEN) achieved an ORR of 87%, a complete remission rate (CRR) of 44%, compared to 32% ORR and 8% CRR with HMAs alone (17).